1 |
Yan L (2002). Liver Surgery. Peking: The People's Medical Publishing House, 263-509.
|
2 |
Zhu S, Shan H, Huang M, et al (2000). The content changes of serum liver fibrosis indicators after transarterial chemoembolization for primary hepatic carcinoma and their clinical significance. J Clin Radiol, 19, 208-9.
|
3 |
Bruix J (1997). Treatment of hepatocellular carcinoma. Hepatology, 25, 259-62.
DOI
ScienceOn
|
4 |
Camma C, Schepis F, Orlando A, et al (2008). Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology, 224, 47-54.
|
5 |
chen MS, Li JQ, Zhang YQ, et al (2002). High does iozedized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol, 8, 74.
|
6 |
Chen Y, Feng Y, Dai L, et al (2003). Screening and evaluation of non-traumatic diagnostic indexes to compensatory hepatic cirrhosis. Chinese Hapar Disease J, 11, 220-5.
|
7 |
Chung JW, Park JH, Han JK, et al (2007). Hepatic tumors: predisposing fators for complications of transeatheter oily chemoembolization. Radiology, 198, 33-40.
|
8 |
Chung JW, Park JH, Han JK, et al (1996). Hepatic tumors: predispo sing factors for complications of transcatheter oily chemoembolization. Radiology, 198, 33-40.
DOI
|
9 |
Feng G, Wu H, Xu L, et al (2002). The related to the fibrotic indicators of primary hepatocellular carcinoma patients after transcatheter arterial chemoembolization. Chinese J of Hepatobiliary Surg, 8, 414-6.
|
10 |
Hu D, Li Z, Wang N, et al (2002). TACE treatment of Hepatic Carcinoma: A Comparative study of low dose versus conventional dose. Clin Radiol J, 23, 502-6.
|
11 |
Ikeda K, Kumada H, Saitoh S, et al (2001). Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis by the cox proportional hazard model. Cancer, 68, 2150-4.
|
12 |
Lu W, Li Y, He X, et al (2004). A comparative study on the changes of serum fibrosis indicators after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. J Interv Radiol, 13, 247-9.
|
13 |
Kamada K, Nakanishi T, Kitamoto M, et al (2001). Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol, 12, 847-54.
DOI
|
14 |
Kamada K, Nakanishi T, Kitamato M, et al (2009). Long-term prognosis of patients undergoing transcatheter arterial chenmoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin liopiodol suspension and doxorubicin hydrocholoride emulsion. J Vasc Interv Radiol, 12, 843-7.
|
15 |
Li H, Hu D, Zhao Y, et al (2000). The relationship between curative effect of hepatic arterial chemoembolization and dose of Iodized Oil. China Hepatol J, 12, 235-6.
|
16 |
Lu W, Lu S (2006). Progress in diagnosis and treatment of liver fibrosis. Int J Digest Dis, 26, 13-6.
|
17 |
Xiao C, Zheng L, Jiang X, et al (1997). Observation of liver damage caused by hepatic arterial chemoembolization. China Radiol J, 31, 777-9.
|
18 |
Lu W, Li Y (2002). Hepatic carcinoma treated with trancatheter arterial chemoembolization. Clin Radiol J, 21, 735.
|
19 |
Lu W, Li Y, Li Z, et al (2003). A comparative study on necrosis and apoptosis of hepatocellular carcinoma cells after TACE with use of low-dose and conventional-dose anticancer drugs. Chinese J Radiol, 37, 232-7.
|
20 |
Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guide lines to evaluate the response to treatment in solidtumors. JNCI, 92, 205-16.
DOI
ScienceOn
|